269 General discussion 8 55. Schepers SA, Sint Nicolaas SM, Haverman L, et al: Real-world implementation of electronic patient-reported outcomes in outpatient pediatric cancer care. Psychooncology 26:951-959, 2017 56. Breitenstein RS, Doane LD, Lemery-Chalfant K: Children’s objective sleep assessed with wristbased accelerometers: strong heritability of objective quantity and quality unique from parentreported sleep. Sleep 44, 2021 57. Schimmer BP, Funder JW: Adrenocorticotropic Hormone, Adrenal Steroids, and the Adrenal Cortex, in Brunton LL, Hilal-Dandan R, Knollmann BC (eds): Goodman & Gilman’s: The Pharmacological Basis of Therapeutics, 13e. New York, NY, McGraw-Hill Education, 2017 58. Koning A, Habets PC, Bogaards M, et al: Mineralocorticoid receptor status in the human brain after dexamethasone treatment: a single case study. Endocr Connect 11, 2022 59. Stith RD, Person RJ, Dana RC: Uptake and binding of [3H]hydrocortisone by various pig brain regions. Brain Res 117:115-24, 1976 60. Born J, DeKloet ER, Wenz H, et al: Gluco- and antimineralocorticoid effects on human sleep: a role of central corticosteroid receptors. Am J Physiol 260:E183-8, 1991 61. Bini J, Parikh L, Lacadie C, et al: Stress-level glucocorticoids increase fasting hunger and decrease cerebral blood flow in regions regulating eating. Neuroimage Clin 36:103202, 2022 62. Koorneef LL, van der Meulen M, Kooijman S, et al: Dexamethasone-associated metabolic effects in male mice are partially caused by depletion of endogenous corticosterone. Front Endocrinol (Lausanne) 13:960279, 2022 63. McGrath P, Pitcher L: ‘Enough is enough’: qualitative findings on the impact of dexamethasone during reinduction/consolidation for paediatric acute lymphoblastic leukaemia. Support Care Cancer 10:146-55, 2002 64. van Litsenburg RR, Huisman J, Hoogerbrugge PM, et al: Impaired sleep affects quality of life in children during maintenance treatment for acute lymphoblastic leukemia: an exploratory study. Health Qual Life Outcomes 9:25, 2011 65. Eiser C, Davies H, Jenney M, et al: HRQOL implications of treatment with dexamethasone for children with acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer 46:35-9, 2006 66. Adams M, Robling M, Grainger J, et al: Quality of life Evaluation in patients receiving Steroids (the QuESt tool): initial development in children and young people with acute lymphoblastic leukaemia. Arch Dis Child 101:241-6, 2016 67. Colloca L, Barsky AJ: Placebo and Nocebo Effects. N Engl J Med 382:554-561, 2020 68. Amanzio M, Benedetti F: Neuropharmacological dissection of placebo analgesia: expectationactivated opioid systems versus conditioning-activated specific subsystems. J Neurosci 19:48494, 1999 69. Eippert F, Bingel U, Schoell ED, et al: Activation of the opioidergic descending pain control system underlies placebo analgesia. Neuron 63:533-43, 2009 70. Schedlowski M, Enck P, Rief W, et al: Neuro-Bio-Behavioral Mechanisms of Placebo and Nocebo Responses: Implications for Clinical Trials and Clinical Practice. Pharmacol Rev 67:697-730, 2015 71. Czerniak E, Oberlander TF, Weimer K, et al: “Placebo by Proxy” and “Nocebo by Proxy” in Children: A Review of Parents’ Role in Treatment Outcomes. Front Psychiatry 11:169, 2020 72. Grelotti DJ, Kaptchuk TJ: Placebo by proxy. BMJ 343:d4345, 2011 73. Haour F: Mechanisms of the placebo effect and of conditioning. Neuroimmunomodulation 12:195200, 2005 74. Suchman AL, Ader R: Classic conditioning and placebo effects in crossover studies. Clin Pharmacol Ther 52:372-7, 1992
RkJQdWJsaXNoZXIy MTk4NDMw